ArticleCurrent hematologic malignancy reports2009
The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Article in Current hematologic malignancy reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- JAK2-V617F mutation among blood donors: A meta-analysis.Saudi medical journal · 2024Pooled it
- Osteolytic bone lesions in patients with primary myelofibrosis: A systematic review.Acta bio-medica : Atenei Parmensis · 2022Pooled it
- Trial
- Haematocrit is invalid for estimating red cell volume: a prospective study in male volunteers.Blood transfusion = Trasfusione del sangue · 2012Trial
- Article
- Incidence, Prevalence, and Survival Outcomes of Patients with Myeloproliferative Neoplasms in the United States: a SEER database analysis, years 2000-2021.Research square · 2026Article
- Gender influences prognosis of classical BCR::ABL1 negative myeloproliferative neoplasms: a retrospective cohort study.Discover oncology · 2025Article
- Evolution of WHO diagnostic criteria in "Classical Myeloproliferative Neoplasms" compared with the International Consensus Classification.Blood cancer journal · 2025Review
- Polycythemia vera disease profile in an African population-experience from a tertiary facility in Ghana.SAGE open medicine · 2023Article
- Case report: Metastatic pancreatic neuroendocrine tumour associated with portal vein thrombosis; successful management with subsequent pregnancies.Frontiers in endocrinology · 2023Article
- International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms.Virchows Archiv : an international journal of pathology · 2023Review
- Volumetric Splenomegaly in Patients With Polycythemia Vera.Journal of Korean medical science · 2022Article
- A study on the correlation between hemoglobin concentration and the storage quality of suspended red blood cells prepared from the whole blood of Tibetan male residents.Frontiers in medicine · 2022Article
- Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics.Cancers · 2021Review
- Volumetric splenomegaly in patients with essential thrombocythemia and prefibrotic/early primary myelofibrosis.International journal of hematology · 2021Article
- Genome editing to model and reverse a prevalent mutation associated with myeloproliferative neoplasms.PloS one · 2021Article
- Pitfalls of delaying the diagnosis of hereditary haemorrhagic telangiectasia.The Journal of international medical research · 2020Article
- Recommendations for Therapeutic Apheresis by the Section "Preparative and Therapeutic Hemapheresis" of the German Society for Transfusion Medicine and Immunohematology.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2019Review
- Genomic characterization of spleens in patients with myelofibrosis.Haematologica · 2018Article
- Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation.Leukemia research reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several international working groups cooperated to propose new diagnostic guidelines for polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) to the steering committee of the World Health Organization. Because JAK2 mutation status presents a decisive diagnostic test in PV, this feature was introduced as a major criterion. Minor criteria, such as characteristic bone marrow morphology, low erythropoietin level, and erythroid colony formation, were kept as supporting parameters. In PMF, major diagnostic criteria were established by histologic features independent of the presence of relevant fibrosis or myelofibrosis with myeloid metaplasia. JAK2 mutation status was restricted to positive findings to exclude reactive myelofibrosis. A decrease in the platelet level was proposed for ET, because vascular complications may occur at lower platelet counts. As with PMF, morphology plays a distinctive role in diagnosis, particularly for its differentiation from early-stage PV or prodromal PMF associated with thrombocytosis.
Indexed as
Identifiers
20425436What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.